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Earlier detection of microalbuminuria in diabetic patients using
a new urinary albumin assay.
Background. Microalbuminuria is regarded as the most im-
portant predictor of high risk for the development of di-
abetic nephropathy. Early detection may allow treatment
to prevent progression to persistent albuminuria and renal
failure. Recent studies have shown that conventional im-
munoassays underestimate urinary albumin concentration, as
albumin in urine may exist in two forms, immuno-reactive and
immuno-unreactive. The present study examines the differen-
tial lead-time for the development of microalbuminuria as mea-
sured by both conventional radioimmunoassay (RIA; measures
immuno-reactive) and high-performance liquid chromatogra-
phy (HPLC; measures total albumin = immuno-reactive plus
immuno-unreactive) analysis in both type 1 and type 2 diabetic
patients.
Methods. Analysis was performed on 511 stored urine sam-
ples collected over the last 13 years from type 1 diabetic patients
who either progressed from normo- to microalbuminuria (pro-
gressors, N =17), or who remained normoalbuminuric (nonpro-
gressors, N = 25) as defined by RIA, and on 634 urine samples
collected from patients with type 2 diabetes defined as either
progressors (N = 24) or nonprogressors (N = 25).
Results. For type 1 progressors, the mean lead-time for the
HPLC assay versus the RIA was 3.9 years, with a 95% CI of
2.1 to 5.6 years. For type 2 progressors, the mean lead-time was
2.4 years with a 95% CI of 1.2 to 3.5 years. There was no signif-
icant difference between the lead-time analysis between type 1
and type 2 diabetic patients.
Conclusion. These results demonstrate that measurement of
total albumin may allow earlier detection of microalbuminuria
associated with diabetic nephropathy.
Microalbuminuria, defined as an albumin excretion
rate (AER) of between 20 and 200 lg/min (30 to 300 mg/
Key words: microalbuminuria, diabetes, immunoassay, high-
performance liquid chromatography, diagnostic specificity, diagnostic
sensitivity.
Received for publication October 6, 2003
and in revised form November 4, 2003
Accepted for publication December 1, 2003
C© 2004 by the International Society of Nephrology
day) as measured by immunochemical methods, is one of
the earliest indicators of diabetic nephropathy in 20% to
30% of type 1 and type 2 diabetic patients [1]. Microal-
buminuria has been confirmed as the best-documented
predictor of high risk for development of diabetic
nephropathy (DN) in patients with either type 1 [2] or
type 2 diabetes [3]. It is imperative to test for microal-
buminuria because early detection and treatment with
antihypertensive agents and improvements in glycemic
control may slow or even prevent progression to per-
sistent albuminuria and end-stage renal failure (ESRF)
[2–5]. In addition to predicting nephropathy, microalbu-
minuria is also a marker of increased risk of cardiovascu-
lar disease, the leading cause of death in diabetic patients
[1, 4, 6].
Recent studies have demonstrated that conventional
immunoassays may underestimate albumin concen-
tration, particularly in urine from diabetic patients,
that is, diabetic patients excrete albumin that is not
detected by immunoassays (immuno-unreactive) [7].
A new albumin assay using high-performance liquid
chromatography (HPLC) (FDA approved) has been
developed which can detect both immuno-reactive al-
bumin plus immuno-unreactive albumin [7]. The ex-
act nature of immuno-unreactive albumin is not known
but may involve conformational changes as a result
of biochemical modification during renal passage. Con-
ventional antibodies generated against native serum al-
bumin do not recognize the modified urinary albumin
[7].
The present study set out to examine the differen-
tial lead-time for the development of microalbuminuria
(AER >20 lg/min) as measured by both conventional ra-
dioimmunoassay (RIA; only measures immuno-reactive
albumin) and HPLC (measures total albumin including
immuno-reactive albumin plus immuno-unreactive albu-
min) in both type 1 and type 2 diabetic patients. Patients
who did not progress to microalbuminuria were also
studied.
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METHODS
Selection of study participants
The Endocrine Unit at the Austin & Repatriation
Medical Center, a tertiary referral center and teach-
ing hospital of the University of Melbourne, Victoria,
Australia, has a database of approximately 2500 diabetic
patients. Twenty-four–hour urine samples from these pa-
tients have been collected and stored at −20◦C for the
past 15 years. Patient records were analyzed retrospec-
tively and chronologically to find patients which satisfied
our inclusion criteria. Only patients attending the En-
docrine Clinic at least every 6 months were eligible for
inclusion. Patients who were found to have >12 years
normoalbuminuria (<20 lg/min) as determined by im-
munoturbidimetry were included in the study and defined
as nonprogressors. Patients who were found to have nor-
moalbuminuria (before transition to microalbuminuria),
where there were at least 3 successive urines >20 lg/min
as determined by immunoturbidimetry, were included in
the study and defined as progressors. Eligible patients
were included chronologically until there was a total of 25
type 1 and 25 type 2 nonprogressors, and 17 type 1 (there
were only this many patients of this type in the database)
and 24 type 2 progressors. Stored urines from each of
these patients were chosen entirely at random, ensuring
that there was a sample every 6 to 12 months. A total
of 511 and 634 urines were examined for the type 1 and
type 2 diabetics, respectively. Immunoturbidimetry was
used clinically to determine AER, and these results were
used retrospectively to determine those patients eligible
for inclusion in the study. There was no normalization of
AER for age or glomerular filtration rate (GFR). Subse-
quently, the urines were reanalyzed by RIA (described
below), first to ensure that there was no storage artefact,
and second to report finite AER levels to be compared
with HPLC analysis because the detection limit of the im-
munoturbidimetry assay used is 6 mg/L, and the detection
limit of the RIA is 16 lg/L.
Clinical evaluation
The following information was recorded in the pa-
tient’s history and then abstracted for this study: pa-
tient’s age and gender, duration of diabetes, HbA1c,
plasma sodium concentration, blood pressure, use of
renin-angiotensin system (RAS) inhibitors, retinopathy
status, and smoking history. No pre-microalbuminuric
(assessed by conventional RIA) patients were studied
while on RAS inhibitors. Blood pressure was measured
after 5 minutes of recumbency using the disappearance
of the Korotkoff sounds. The examination of the ocular
fundi was by direct ophthalmoscopy after pupillary di-
latation. Retinal lesions were categorized as either back-
ground or proliferative retinopathy.
Measurement of urinary albumin excretion
Total urinary albumin (immuno-reactive plus immuno-
unreactive) excretion was measured using a newly devel-
oped HPLC assay (AusAm Biotechnologies, Inc., Santa
Monica, CA, USA). Aliquots from 24-hour urine collec-
tions were stored at –20◦C until analysis. Aliquots of un-
treated urine (25 lL) were injected onto a Zorbax Bio
series analytic, GF-250 column (either 9.4 mm inner di-
ameter × 25 mm or 4.6 mm inner diameter × 25 mm)
(Agilent Technologies, Wilmington, DE, USA) and ana-
lyzed using an Agilent 1100 HPLC system as previously
described [7]. The mobile phase was phosphate-buffered
saline (PBS) run at a flow rate of either 1 mL/min or
0.5 mL/min. The albumin peak in the urine sample was
generally identified to within ±2% of the elution time of
the monomer albumin standard. Low albumin concentra-
tion samples measured by HPLC were expressed as being
<2 lg/mL. The intra-assay coefficients of variation (CVs)
were 5.6% and 6.0% at concentrations of 44.7 mg/L and
141 mg/L, respectively, and the interassay CV was 2.4%
at 95.9 mg/L.
Immunoreactive intact urinary albumin concentration
was measured by two methods. The major method was
a double antibody RIA with CVs of 9.2% and 4.8%
at concentrations of 12.2 mg/L and 33 mg/L, respec-
tively, and detection limit of 16 lg/L using an albu-
min standard (Fraction V; Sigma, St. Louis, MO, USA)
that was made volumetrically. Antihuman albumin an-
tibody was from Dako Corporation (Carpinteria, CA,
USA).
Immunoreactive intact urinary albumin concentra-
tion was also measured by immunoturbidimetry using a
Dade-Behring Turbitimer with reagents and calibrators,
supplied by Dade-Behring Marburg GmbH (Marburg,
Germany). The CVs were 4.1%, 2.2%, and 4.2% at con-
centrations of 10.6 mg/L, 43.2 mg/L, and 77.9 mg/L,
respectively, and detection limit of 6 mg/L. The RIA
and immunoturbidimetry assays have been shown to be
equivalent [8, 9].
Laboratory assays
Urine and plasma electrolyses were measured on
a Hitachi 911 Automatic Analyzer (Roche Diagnos-
tics, Mannheim, Germany). Glycosylated hemoglobin
(HbA1c) was measured by automated HPLC (Biorad
Diamat, Richmond, CA, USA) or by HbA1c Analyzer
(Primus; Kansas City, MO, USA). Fasting lipids were
measured by enzymatic calorimetry.
Statistical analysis
Data are expressed as mean ± standard error, where
N represents the number of determinations. Data analy-
sis was performed using Minitab version 12.23 (Minitab,
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Inc., State College, PA, USA). Data was analyzed for nor-
mality using the Anderson-Darling Normality test [10].
The mean and median difference in time taken to reach
microalbuminuria (AER >20 lg/min as determined by
the geometric mean of three consecutive urine samples)
as measured by HPLC versus RIA were determined in-
cluding 95% CI. Diagnostic specificity and diagnostic sen-
sitivity were obtained using the Normal approximation
to the Bionomial Distribution. Comparison of the clini-
cal characteristics between the study patients were per-
formed using a two sample t test using SigmaStat (SPSS,
Chicago, IL, USA). P < 0.05 was considered statistically
significant.
Definitions
Persistent microalbuminuria is defined as being present
when the geometric mean of three consecutive urine
samples exceeds 20 lg/min by RIA. Nonprogressors
are defined as patients with >12 years normoalbumin-
uria (AER <20 lg/min) as determined by immunotur-
bidimetry. Progressors are defined as patients who were
found to have normoalbuminuria (before transition to
microalbuminuria), where there are at least 3 succes-
sive urines with AER >20 lg/min as determined by
immunoturbidimetry.
RESULTS
Clinical characteristics for the type 1 diabetic progres-
sors (N = 17) and nonprogressors (N = 25) were as-
certained (Table 1). Both progressors and nonprogres-
sors had similar ages and duration of diabetes. One
third of progressors and 44% of nonprogressors were
female. There was no significant difference in systolic
blood pressure between progressors and nonprogressors
at the start or at the end of the study. Systolic blood
pressure increased in both groups over the study period.
Diastolic blood pressure was significantly different be-
tween progressors and nonprogressors at the start but
not at the end of the study. The mean HbA1c was signifi-
cantly higher in progressors over the course of the study.
There was a significant difference in the final plasma
sodium between progressors and nonprogressors. The
severity of retinopathy was greater in progressors than
nonprogressors. A greater proportion of smokers were
progressors.
Clinical characteristics for the type 2 diabetic progres-
sors (N = 24) and nonprogressors (N = 25) were also
ascertained (Table 2). Both progressors and nonprogres-
sors had similar ages and duration of diabetes. There were
approximately equal numbers of males and females in
the progressor groups, and 71% females in nonprogres-
sor groups. There was no significant difference in systolic
blood pressure between progressors and nonprogressors
at the start or at the end of the study. Diastolic blood pres-
sure was significantly different between progressors and
Table 1. Clinical characteristics of the type 1 diabetic nonprogressors
and progressors (mean ± standard error)
Non-
progressors Progressors
(N = 25) (N = 17) Significance
Age at start years 37 ± 3 37 ± 3 NS
Sex (F/M) 11/14 6/11
Duration of diabetes 10.9 ± 2.0 12.5 ± 2.4 NS
at start years
Mean duration of urine 11.4 ± 0.2 8.5 ± 0.6 P < 0.0001
sampling per patient years
Total number of 305 206
urines analyzed
Average time interval 0.9 0.7
per urine sample years
SBP at start mm Hg 121 ± 2 124 ± 6 NS
SBP at end mm Hg 134 ± 4 143 ± 6 NS
DBP at start mm Hg 74 ± 1 79 ± 2 P = 0.03
DBP at end mm Hg 76 ± 2 80 ± 2 NS
HbA1c at start % 8.2 ± 0.4 9.6 ± 0.5 P = 0.03
HbA1c at end % 7.5 ± 0.2 9.4 ± 0.4 P < 0.0001
Plasma sodium excretion 140 ± 0.5 138 ± 1 P = 0.03
at end mmol/24h
Retinopathy status 14/8/3 3/8/6
at end (N/B/P)
Antihypertensive therapy 0 0
at start %
Antihypertensive therapy 12 65
at end %
Smoking history 3/22 7/10
at start Y/N
Smoking history 0/25 4/13
at end Y/N
Abbreviations are: SBP, systolic blood pressure; DBP, diastolic blood pressure;
B, background retinopthy; P, proliferative retinopathy; Y, yes; N, no.
nonprogressors at the start but not at the end of the study.
HbA1c was not significantly different for progressors and
nonprogressors over the study period. There was no dif-
ference in the final plasma sodium between progressors
and nonprogressors. The severity of retinopathy was not
significantly different between progressors and nonpro-
gressors. There were a similar proportion of smokers in
both groups.
The urines from patients examined in this study were
studied up until February of 2001. We have subsequently
done a follow-up study of the patients until August of
2003. There was no follow-up data available for 6/25 and
9/25 of the type 1 and type 2 nonprogressors, respectively,
and 8/17 and 8/24 of the type 1 and type 2 progressors,
respectively. This was a result of death or discontinued
attendance at the clinic. None of the remaining nonpro-
gressors developed microalbuminuria as measured by im-
munoturbidimetry. Table 3 shows the number of type 1
and type 2 progressors, for whom there was follow-up
data available, with normo-, micro-, or macroalbumin-
uria in February of 2001 compared with August of 2003
as measured by immunoturbidimetry.
Stability of stored samples in relation to immunoassays
The equivalence of the immunoturbidimetry assay and
RIA at an albumin concentration >6 mg/L has been
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Table 2. Clinical characteristics of the type 2 diabetic nonprogressors
and progressors (mean ± standard error)
Non-
progressors Progressors
(N = 25) (N = 24) Significance
Age at start years 59 ± 2 61 ± 2 NS
Sex (F/M) 17/8 13/11
Duration of diabetes at
start years
11.7 ± 1.5 9.0 ± 1.4 P = 0.19
Mean duration of urine
sampling per patient
years
10.7 ± 0.4 7.5 ± 0.4 P < 0.0001
Total number of urines
analyzed
291 343
Average time interval per
urine sample years
0.9 0.5
SBP at start mm Hg 147 ± 5 147 ± 4 NS
SBP at end mm Hg 147 ± 4 153 ± 4 NS
DBP at start mm Hg 76 ± 2 86 ± 2 P = 0.0013
DBP at end mm Hg 80 ± 2 80 ± 1 NS
HbA1c at start % 8.3 ± 0.4 8.8 ± 0.4 NS
HbA1c at end % 7.9 ± 0.2 8.7 ± 0.6 NS
Plasma sodium excretion
at end mmol/24h
142 ± 1 140 ± 1 NS
Retinopathy status at end
(N/B/P)
18/4/3 16/4/4
Antihypertensive therapy
at start %
4 12.5
Antihypertensive therapy
at end %
44 50
Smoking history at start
Y/N
3/22 4/21
Smoking history at end
Y/N
2/23 4/21
Abbreviations are: SBP, systolic blood pressure; DBP, diastolic blood pressure;
B, background retinopthy; P, proliferative retinopathy; Y, yes; N, no.
Table 3. Number of type 1 and type 2 progressors, for whom there
was follow-up data available, with normo-, micro-, or
macroalbuminuria in February 2001 compared with August 2003 as
measured by immunoturbidimetry
Type 1 Type 2
Sept. 2001 Aug. 2003 Sept. 2001 Aug. 2003
Normoalbuminuria 0/9 1/9 0/16 1/16
Microalbuminuria 6/9 4/9 13/16 13/16
Macroalbuminuria 3/9 4/9 3/16 2/16
previously reported [8, 9]. In this study, linear regression
analysis of stored diabetic urines measured by immuno-
turbidimetry at the time of collection and by RIA (range 7
to 2500 mg/L) in June through September of 2001 showed
good agreement (Fig. 1), demonstrating that there is no
storage artefact for urinary albumin; y = 0.93x + 0.5
(N = 92, r = 0.97), where x and y represent results ob-
tained by RIA and immunoturbidimetry, respectively.
Immuno-unreactive albumin is also not formed as a re-
sult of storage because it is present in fresh diabetic urine
[7].
The onset of persistent microalbuminuria as determined
by HPLC compared with RIA
The differential lead-time for the development of mi-
croalbuminuria (AER >20 lg/min) as determined by
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Fig. 1. Comparison of urinary albumin excretion measured by im-
munoturbidimetry at the time of urine collection (spanning 13 years)
and measured by radioimmunoassay (RIA) (range 7–2500 mg/L) in
June to September, 2001. y = 0.93x + 0.5 (N = 92, r = 0.97), where
x and y represent results obtained by RIA and immunoturbidimetry,
respectively. Predicted 95% CIs are also shown.
both RIA and HPLC was examined in both type 1 and
type 2 diabetic patients. Among type 1 progressors, the
mean lead-time for the HPLC assay versus the RIA was
3.9 years, with a 95% CI of 2.1 to 5.6 years (Fig. 2). For
type 2 progressors, the mean lead-time was 2.4 years with
a 95% CI of 1.2 to 3.5 years (Fig. 3). In both cases the
Anderson-Darling Normality Test [10] showed that the
individual lead times were not normally distributed, as
would be expected from the non-negative nature of the
data; however, the CIs remain valid because of the Cen-
tral Limit Theorem. There was no significant difference
between the lead-time analysis between type 1 and type
2 diabetic patients (two-sample t test, P = 0.14).
Diagnostic specificity and sensitivity
CIs and hypothesis tests for the proportions of false
positives (diagnostic specificity) and false negatives (di-
agnostic sensitivity) were obtained using the Normal ap-
proximation to the Binomial distribution. For the type
1 nonprogressors there was no significant difference
(P = 0.056) between the false positives for the HPLC
assay (6/280 urines, 2.1%, CI of 0.8–4.6) and RIA (1/280
urines, 0.4%, CI of 0–2.0). For the type 2 nonprogressors,
the false positives for the HPLC assay (28/265 urines,
10.6%, CI of 7.1–14.9) were significantly higher (P <
0.0005) than those for the RIA (0/265 urines, 0%, CI of
0–1.4). For the type 1 progressors, the false negatives for
the RIA (67/121 urines, 55.4%, CI of 46.1–64.4) were sig-
nificantly higher (P < 0.0005) than those for the HPLC
(0/121 urines, 0%, CI of 0–3.0). Similarly, for the type 2
progressors the false negatives for the RIA (78/190 urines,
41.1%, CI of 33.9–48.4) were significantly higher (P <
0.0005) than those for the HPLC (5/190 urines, 2.6%, CI
of 33.9–48.4).
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Fig. 2. Differential lead-time analysis for the
development of microalbuminuria [albumin
excretion rate (AER) >20 lg/min as de-
termined by the geometric mean of three
consecutive urine samples] as determined
by both radioimmunoassay (RIA) and high-
performance liquid chromatography (HPLC)
for type 1 diabetic patients. (A) Histogram
and best fitting Normal distribution showing
individual patient data for the time taken (in
years) for the detection of microalbuminuira
as measured by HPLC versus RIA. (B) Box-
plot showing median and quartiles for the
differential time taken for the detection of
microalbuminuria. (C) 95% CI for the mean
difference in time taken for the detection of
microalbuminuria, and (D) 95% CI for the
median difference in time taken for the de-
tection of microalbuminuria.
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Fig. 3. Differential lead-time analysis for the
development of microalbuminuria [albumin
excretion rate (AER) >20 lg/min as de-
termined by the geometric mean of three
consecutive urine samples] as determined
by both radioimmunoassay (RIA) and high-
performance liquid chromatography (HPLC)
for type 2 diabetic patients. (A) Histogram
and best fitting Normal distribution showing
individual patient data for the time taken (in
years) for the detection of microalbuminuira
as measured by HPLC versus RIA. (B) Box-
plot showing median and quartiles for the
differential time taken for the detection of
microalbuminuria. (C) 95% CI for the mean
difference in time taken for the detection of
microalbuminuria, and (D) 95% CI for the
median difference in time taken for the de-
tection of microalbuminuria.
DISCUSSION
This study demonstrates that the new HPLC assay is
able to detect microalbuminuria far earlier than a con-
ventional immunoassay for both type 1 and type 2 dia-
betic patients. Correspondingly, the proportion of false
negatives associated with the conventional immunoas-
say is profoundly high (range 41% to 55%) compared
with the proportion of false positives for the HPLC as-
say (<11%). Overall, most of the false positives were
associated with relatively older patients within each non-
progressor group. This is most probably a result of
age-dependent microalbuminuria that appears in the gen-
eral population [11]. We have also shown in a previous
study of a nondiabetic control group that the proportion
of false positives for the HPLC is less than 4% [7]. Despite
the fact that this is a pilot study with a small number of pa-
tients, the results stress the need for an accurate measure-
ment of AER in diabetic patients, and that total albumin
may provide a more accurate and earlier detection of mi-
croalbuminuria than conventional immunoassay. These
findings should be confirmed in a larger study.
Urine consists of a complex mixture of immuno-
reactive and immuno-unreactive components, as we have
previously described [7, 12–14]. Immunoassays can only
detect immuno-reactive intact urinary albumin [7, 12–14]
as well as albumin fragments >12 kD and polymer al-
bumin aggregates [15–17]; however, the exact nature by
which albumin components are detected by immunoas-
says remains poorly defined. HPLC analysis of urinary
albumin is well defined because this assay is able to detect
both intact immuno-reactive albumin, as well as intact
immuno-unreactive albumin [7]. Currently, immunoas-
says and HPLC are unable to quantitatively measure
albumin-derived fragments (<10 kD).
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CONCLUSION
The results presented in this study suggest that conven-
tional immunochemical-based assays considerably un-
derestimate urinary albumin excretion. The discrepancy
between the HPLC assay and immunochemical-based as-
says demonstrates that the HPLC albumin assay may
provide a relatively early diagnosis of incipient kidney
disease at a diagnostic threshold of 20 lg/min.
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